5 Most Undervalued Growth Stocks to Buy According to Analysts

3. Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Stock Upside Potential: 43.46%

Forward P/E: 4.68

Number of Hedge Fund Holders: 31

Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the most undervalued growth stocks to buy, according to analysts. On March 12, Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced the appointment of David Ramsay as the interim Chief Financial Officer, pending the appointment of a permanent CFO.

Ramsay takes over as CFO with over 30 years of experience in strategic financial leadership across the biotechnology and life sciences sectors. He also boasts of extensive experience in capital markets, corporate finance, and investor relations. He previously served as the company’s CFO from 2003 to 2009 and again from 2013 to 2015. During his tenure, the company evolved from a private company to a billion-dollar entity.

Earlier on March 11, Halozyme Therapeutics outlined its growth strategy at The Citizens Life Sciences Conference, projecting $1.7–$1.8 billion in revenue for the year, a 22%–30% increase. CEO Helen Torley emphasized the strength of ENHANZE drug‑delivery royalties, expected to reach $1.1–$1.2 billion, alongside contributions from products like DARZALEX FASPRO and VYVGART HYTRULO. Despite ongoing patent litigation with Merck, Halozyme sees royalties unaffected and plans at least three new deals in 2026.

Financially, adjusted EBITDA is forecast at $1.1–$1.2 billion, supported by acquisitions such as Elektrofi and Surf Bio, which enhance its Hypercon technology portfolio. With seven ENHANZE products in development and multiple trials starting this year, Halozyme aims to have 40 drugs approved or in development by 2028, positioning ENHANZE and Hypercon as long‑term growth drivers.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) is a biotechnology company focused on developing and commercializing disruptive drug delivery technologies, primarily using its proprietary ENHANZE® technology. The technology uses recombinant human hyaluronidase (rHuPH20) to enable rapid, high-volume subcutaneous injection of drugs typically administered intravenously.